Experts Platform launch will Enable 60,000+ Researchers at 38 Institutions to Collaborate
COLUMBIA, S.C., March 3 /PRNewswire-FirstCall/ -- Collexis Holdings Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic search and knowledge discovery software, announced today the launch of the Collexis Expert Platform for Translational Research drawing on the research profiles of 38 institutions and their more than 60,000 life science researchers. The platform is available to Collexis clients who are grantees of the Clinical Translational Science Awards (CTSA's) from the National Institutes of Health. Institutions that are subscribers to the service will be able to search, rank, and visualize experts from over 38 institutions.
"One of the most important goals in biomedical research is to accelerate the process from discovery to patient care, which is a priority of a number of funding programs," said Dr. Christian Herzog, Managing Director at Collexis. "Collexis is a software company focused on biomedical research. We have already launched the free social networking site www.biomedexperts.com and we are now providing a system which will proactively suggest which researchers should be collaborating across institutions."
"It is important to note," added Dr. Herzog, "that NIH has not endorsed this platform, and that our efforts in translational research are independent. NIH is one of our clients for Expertise Profiling Software, but they are not working with us in the launch of this platform."
The new offering gives Collexis users a unique competitive advantage. It allows a researcher to identify potential partners from their organization and from published researchers at institutions with CTSA grants on any combination of biomedical research topic(s), and it automatically recommends collaborators. Finally, the system will track and identify collaboration patterns among organizations allowing Collexis to give clients more information about how researchers work together and signaling ways the cooperation between basic and clinical researchers and institutions can be improved.
The Collexis Expert Platform for Translational Research approach to profiling life science researchers has become a standard with research intensive institutions. Current clients include
About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with operations in Cincinnati, Ohio and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic;
Disclaimer: National Institutes of Health (NIH) and NIH's CTSA Program are not considered a supporter or partner of Collexis. Reference to NIH or CTSA consortium in the above shall not be construed as a Government endorsement nor does it obligate NIH to a position on or about the Collexis Software.
Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company's Expert Platform for Translational Research. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-K for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.
|SOURCE Collexis Holdings, Inc.|
Copyright©2009 PR Newswire.
All rights reserved